Voyager Therapeutics stock tumbles after IND application delayed
Despite the setback with VY9323, Voyager Therapeutics anticipates IND filings in 2025 for gene therapy candidates targeting GBA1 Parkinson’s and other GBA1-mediated diseases, as well as Friedreich’s ...
Voyager Therapeutics shifts focus for ALS therapy
LEXINGTON, Mass. - Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology firm focused on neurogenetic medicines with a market capitalization of $290 million, announced today it is reassessing its ...
Voyager to assess alternate payloads for SOD1 ALS gene therapy program
Voyager Therapeutics (VYGR) has decided to assess alternate payloads related to its gene therapy program for superoxide dismutase 1 amyotrophic ...
Voyager Provides Update on SOD1 ALS Gene Therapy Program
Company to assess alternate payloads; no changes planned to novel capsid component - - Resulting shift of timeline and costs ...
Deutsche Bank sets Neurocrine stock with $138 price target
Deutsche Bank (ETR:DBKGn) began coverage on Neurocrine Biosciences (NASDAQ:NBIX) stock, assigning a Hold rating and setting a price target of $138. The bank's analyst noted that with a current market ...
Neurocrine initiated with a Hold at Deutsche Bank
Deutsche Bank initiated coverage of Neurocrine (NBIX) with a Hold rating and $138 price target Maximize Your Portfolio with Data Driven ...
Neurocrine Biosciences (NASDAQ:NBIX) Price Target Lowered to $163.00 at Guggenheim
Neurocrine Biosciences (NASDAQ:NBIX – Free Report) had its price objective reduced by Guggenheim from $165.00 to $163.00 in a report published on Monday,Benzinga reports. They currently have a buy ...
Why Neurocrine Biosciences Stock Sank Today
Despite better-than-expected profitability in the fourth quarter, which it reported late last week, Neurocrine Biosciences (NASDAQ: NBIX) hasn't been wowing analysts lately. On Mo ...